In the Literature

Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with CLL

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - In the Literature, Leukemia

Chemoimmunotherapy with chlor­ambucil plus obinutuzumab or bendamustine plus rituximab is standard frontline treatment for older patients with chronic lymphocytic leukemia (CLL). However, chemoimmunotherapy is associated with toxic effects, and the risk increases with age. For patients with CLL, frontline ibrutinib monotherapy is widely used in clinical practice. The benefit of this Bruton’s tyrosine kinase (BTK) inhibitor versus standard chemoimmunotherapy remains a critical consideration, which led researchers to conduct a head-to-head phase 3 study to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. [ Read More ]

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - In the Literature, Ovarian Cancer

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. In a recent study, researchers evaluated the efficacy of upfront maintenance therapy with olaparib in patients with newly diagnosed, advanced BRCA-positive ovarian cancer. [ Read More ]

Sunitinib After Nephrectomy Benefits Some Patients with Advanced Kidney Cancer

October 2018, Vol 9, No 3 - In the Literature

Nephrectomy has been the standard of care in metastatic renal-cell carcinoma for 20 years. However, its role in treating patients with advanced disease in the era of targeted therapy has been brought into question. In the CARMENA study, researchers assessed the benefit of initial nephrectomy followed by targeted therapy with sunitinib (Sutent) in patients with metastatic kidney cancer versus the benefits provided by su­nitinib monotherapy. [ Read More ]

Talazoparib, a New PARP Inhibitor, Shows Significant Benefit in Patients with Breast Cancer and BRCA Mutation

October 2018, Vol 9, No 3 - In the Literature

Talazoparib, an oral investigational poly (ADP-ribose) polymerase (PARP) inhibitor, is currently being evaluated in advanced breast cancer with BRCA mutation and other cancer types. Talaz­oparib’s dual mechanism of action has the potential to induce tumor cell death by blocking PARP enzyme activity and trapping PARP on the sites of DNA damage. [ Read More ]

In the Literature – November 2016

November 2016, Vol 7, No 10 - In the Literature

  • Gaps in Use of Tyrosine Kinase Inhibitors in Medicare Beneficiaries with Chronic Myeloid Leukemia
  • Adding Daratumumab to Standard Regimen Extends Progression-Free Survival in Patients with Multiple Myeloma
  • Mutations Responsible for Relapse Despite PD-1 Therapy Uncovered in Melanoma
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
[ Read More ]

In the Literature – October 2016

October 2016, Vol 7, No 9 - In the Literature

In This Article Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma Addition of Elective Neck Dissection Reduces Overall Costs in Patients with Oral Cavity Cancer 70-Gene Signature Assists Clinicians in Breast Cancer Treatment Decision-Making Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia Many patients with B-cell acute lymphoblastic leukemia (ALL) who achieve complete remission will have disease relapse. Because of the poor prognosis for adults with relapsed ALL, investigators assessed the efficacy and safety [ Read More ]